Abstract
A prospective multicenter study of cryptococcal immune reconstitution inflammatory syndrome (IRIS) was conducted as a substudy of the Bacteriology and Mycology Study Group 3-01. Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS. No association between the timing of HAART initiation and the diagnosis of IRIS was identified. Increased baseline serum cryptococcal antigen (CrAg) titer was a risk factor for cryptococcal IRIS.
Publication types
-
Comparative Study
-
Multicenter Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
AIDS-Related Opportunistic Infections / blood
-
AIDS-Related Opportunistic Infections / complications*
-
AIDS-Related Opportunistic Infections / drug therapy
-
AIDS-Related Opportunistic Infections / microbiology
-
Acquired Immunodeficiency Syndrome / blood
-
Acquired Immunodeficiency Syndrome / complications*
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Acquired Immunodeficiency Syndrome / microbiology
-
Amphotericin B / therapeutic use
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Antifungal Agents / therapeutic use
-
Antigens, Fungal / blood
-
Antiretroviral Therapy, Highly Active
-
Clinical Trials, Phase II as Topic
-
Fluconazole / therapeutic use
-
Humans
-
Immune Reconstitution Inflammatory Syndrome / blood
-
Immune Reconstitution Inflammatory Syndrome / complications*
-
Immune Reconstitution Inflammatory Syndrome / drug therapy
-
Immune Reconstitution Inflammatory Syndrome / epidemiology
-
Immunocompromised Host
-
Incidence
-
Kaplan-Meier Estimate
-
Logistic Models
-
Meningitis, Cryptococcal / blood
-
Meningitis, Cryptococcal / complications*
-
Meningitis, Cryptococcal / drug therapy
-
Meningitis, Cryptococcal / epidemiology
-
Proportional Hazards Models
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Time Factors
Substances
-
Anti-HIV Agents
-
Antifungal Agents
-
Antigens, Fungal
-
Amphotericin B
-
Fluconazole